GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » Net Margin %

Sagimet Biosciences (STU:0O2) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Sagimet Biosciences's Net Income for the three months ended in Dec. 2024 was €-15.47 Mil. Sagimet Biosciences's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Sagimet Biosciences's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Sagimet Biosciences's Net Margin % or its related term are showing as below:


STU:0O2's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -132.42
* Ranked among companies with meaningful Net Margin % only.

Sagimet Biosciences Net Margin % Historical Data

The historical data trend for Sagimet Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences Net Margin % Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial - - - -1,393.78 -

Sagimet Biosciences Quarterly Data
Dec19 Mar20 Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sagimet Biosciences's Net Margin %

For the Biotechnology subindustry, Sagimet Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Net Margin % falls into.


;
;

Sagimet Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sagimet Biosciences's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-43.516/0
= %

Sagimet Biosciences's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-15.472/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sagimet Biosciences  (STU:0O2) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Sagimet Biosciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagimet Biosciences Business Description

Traded in Other Exchanges
Address
155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines